title: HLA-B*58:01 strongly associates with allopurinol-induced adverse drug reactions in a Japanese sample population.
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Niihara
authors.forename: Sakae
authors.initials: S
authors.lastname: Kaneko
authors.forename: Takahumi
authors.initials: T
authors.lastname: Ito
authors.forename: Takashi
authors.initials: T
authors.lastname: Sugamori
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Takahashi
authors.forename: Kunie
authors.initials: K
authors.lastname: Kohno
authors.forename: Eishin
authors.initials: E
authors.lastname: Morita
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000493:Allopurinol / Q000009:adverse effects*; D044466:Asian People; D016022:Case-Control Studies; D064420:Drug-Related Side Effects and Adverse Reactions; D004890:Erythema / Q000188:drug therapy / Q000235:genetics; D005260:Female; D006074:Gout Suppressants / Q000009:adverse effects; D015235:HLA-B Antigens / Q000235:genetics*; D006801:Humans; D007564:Japan; D008297:Male; D016017:Odds Ratio; D010597:Pharmacogenetics; D013262:Stevens-Johnson Syndrome / Q000188:drug therapy / Q000235:genetics
chemical_list: D006074:Gout Suppressants; D015235:HLA-B Antigens; C500126:HLA-B*58:01 antigen; D000493:Allopurinol